

February 2, 1971

Dr. Edgar Grunwaldt
Geigy Pharmaceuticals
Ardsley, New York

Dear Ed,

Enclosed are the interim reports of our EEG pilot study of GPA 1714 in volunteers. We have defined a dosage that is safe and which alters the EEG of our volunteers. The preliminary data is that of a centrally active compound with an EEG profile usually associated with relaxation and euphoria.

I have made the necessary inquiries about the effects of *l*-Dopa on EEG and have just received the citations necessary to compare the effects of GP 41299 to *l*-Dopa.

I trust these data are useful.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kt